Please login to the form below

Not currently logged in
Email:
Password:

Glenmark settles with Astellas/ Triax

Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin

India-based generics manufacturer Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin.

The suit relates to an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a form of hydrocortisone butyrate cream, Glenmark's generic equivalent of Locoid Lipocream, currently registered by Astellas and licensed to Triax.

Under the settlement and licence agreement, Glenmark will be permitted to market and distribute its version of the cream under a royalty-bearing licence from Astellas and Triax in the US by the end of 2013.

In a statement, Glenmark said it believed it was entitled to 180 days of exclusivity to market the product as the first generic company to file a related ANDA.

According to IMS Health data, Locoid Lipocream had sales of around $38m for 2010.

25th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics